United Therapeutics (UTHR) Gross Profit (2009 - 2026)

United Therapeutics has disclosed Gross Profit across 18 years of filings, most recently posting $648.1 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $648.1 million, down 7.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 2.99% YoY), and the FY2025 annual result was $2.8 billion, up 8.98% from the prior year.
• Gross Profit came in at $648.1 million for Q1 2026 at United Therapeutics, down from $686.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $711.0 million in Q2 2025 to a low of $432.7 million in Q4 2022.
• The 5-year median for Gross Profit is $604.8 million (2024), against an average of $580.5 million.
• Across the five-year window, Gross Profit soared 33.04% in 2024 and dropped 7.66% in 2026, its largest moves.
• United Therapeutics' Gross Profit stood at $432.7 million in 2022, then rose by 25.65% to $543.7 million in 2023, then climbed by 21.39% to $660.0 million in 2024, then advanced by 4.06% to $686.8 million in 2025, then declined by 5.63% to $648.1 million in 2026.
• The last three Gross Profit figures came in at $648.1 million (Q1 2026), $686.8 million (Q4 2025), and $698.6 million (Q3 2025), per Business Quant data.